H3 Biomedicine

Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation

More than 80% of patients with the refractory anemia with ring sideroblasts subtype of myelodysplastic syndrome (MDS) have mutations in… Read More

Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins

Mutations in genes encoding splicing factors (which we refer to as spliceosomal genes) are commonly found in patients with myelodysplastic… Read More

H3 Biomedicine to Begin Trials of First-Ever Gene-Splicing Cancer Drug

Kendall Square-based cancer biotech H3 Biomedicine, created five years ago by Japanese drug firm Eisai, will bring its first drug… Read More

H3 Biomedicine Receives FDA Acceptance for Investigational New Drug Application Novel Hematologic Compound Bolsters Company’s Emerging Drug Pipeline

H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member… Read More

H3 Biomedicine and Selvita Extend Precision Cancer Medicines Collaboration

Companies Achieve Multiple Scientific Goals for Two Novel Oncology Targets Read More

Foundation Medicine and H3 Biomedicine Announce Collaboration to Develop Precision Therapies for Cancer

Read More

Foundation Medicine, H3 Biomedicine Partner to Develop Cancer Drugs

A partnership announced today between two Cambridge companies, Foundation Medicine (Nasdaq: FMI) and H3 Biomedicine, is further evidence of the… Read More

Total Synthesis of 6-Deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 Cancer Cell Line

A total synthesis of the natural product 6-deoxypladienolide D (1) has been achieved. Two noteworthy attributes of the synthesis are… Read More

Synthesis and Structure-Activity Relationships of Novel, Potent, Orally Active Hypoxia-Inducible factor-1 Inhibitors

Hypoxia-inducible factor-1 (HIF-1) is the chief transcription factor regulating hypoxia-driven gene expression. HIF-1 overexpression is associated with poor prognosis in… Read More

NAMPT Is the Cellular Target of STF-31-Like Small-Molecule Probes

The small-molecule probes STF-31 and its analogue compound 146 were discovered while searching for compounds that kill VHL-deficient renal cell… Read More